You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a blood test for breast cancer detection

    SBC: INTEGRATED TECHNOLOGIES AND SRVCS INTRNTL            Topic: N/A

    DESCRIPTION (provided by applicant): Mammography is the benchmark for breast disease detection and diagnosis. However, it can miss 10-15% of early stage breast cancers, and it is unable to distinguish between benign and malignant lesions with certainty. Av ailability of an alternate method e.g. biomarker based, which allows early detection/precise distinction between benign disease and breast canc ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Profiling ER, PR, EGFR and HER2 in Breast Cancer Using Multiplex Tissue Immusta

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies, including Herceptin. and novel tyrosine kinase inhibitors. 20/20 will utilize its proprietary Layered Expr ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Inhaled nisin as an emergency intervention against antibiotic sensitive or resist

    SBC: AFG BIOSOLUTIONS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The deliberate release of Bacillus anthracis spores remains an imminent threat both in terms of bioterrorism and biowarfare. Individuals who inhale these spores are at extreme risk of infection and death from anthrax. C urrent prophylaxis and therapy in the event of B. anthracis spore inhalation fall into two categories. Vaccination to protect against future ex ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Add-on module for ONCAD for diagnosing infiltrating lobular carcinoma

    SBC: Alan Penn & Associates Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The specific aim of this study is to develop an add-on module for the ONCAD breast MRI CAD system that will provide radiologists with additional assistance when they have suspicion of the presence of infiltrating lobula r carcinoma (ILC). The proposed research will investigate the possibility of developing, training and evaluating an ILC- specific algorithm tha ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Generation of a Modified DT_IL3 Fusion Toxin

    SBC: ANJIN GROUP, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A number of protein fusion toxins, composed of the diphtheria toxin (DT) toxophore and a targeting ligand, have been assembled and tested in Phase I clinical trials for the treatment of leukemias. To date, the only FDA approved protein fusion toxin is ONTAK. ONTAK is a DT, interleukin-2 receptor-targeted fusion toxin used to treat persistent or recurrent, cuta ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin

    SBC: ANJIN GROUP, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial c ell monolayers. The goals of this Phase I proposal are to evaluate two, in vivo models of vascular leakage, selecting one model for further in ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. In vivo RNAi nanoparticle cancer gene function reagent

    SBC: APARNA BIOSCIENCES CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): In spite of recent advances, cancer remains a major killer posing a dire need for more effective therapy, and unfortunately this is particularly true for metastatic non-small cell lung cancer (NSCLC), which afflicts an extremely large number of patients and is one of the least treatable cancers. With the growing success of targeted therapeutics, it has become ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Hybrid synthetic targeted lenti-VLP nanoparticle for gene delivery

    SBC: APARNA BIOSCIENCES CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): A need for better gene delivery has blocked the potential advancement in biomedical research and most critically development of better therapeutics that operate at the gene function level. This problem is most acute for non-dividing cells, which in fact are the predominant cell type. Thus the considerable interest in gene therapy has narrowed considerably to e ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

    SBC: Apogee Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Sphingolipids are being increasingly recognized as key mediators of inflammatory cascades of critical importance in multiple diseases, including rheumatoid arthritis and osteoarthritis. Most importantly, sphingosine 1-phosphate produced by sphingosine kinase (SK) mediates the effects of tumor necrosis factor-1 and interleukin-12, pro-inflammatory cytokines ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR PHASE I- TOPIC 247- PORTABLE E-TECHNOLOGY DIET AND PHYSICAL ACTIVITY TOOLS F

    SBC: APPLIED MEDIA ANALYSIS, INC.            Topic: N/A

    Applied Media Analysis, Inc (AMA) proposes to collaborate with the George Washington University Weight Management Program and Peaksware LLC to demonstrate the technical feasibility of MobileVision DietMonitor, a software-based solution which uses existing camera-enabled smart phones to provide enhanced capabilities for diet and health monitoring. Our system will allow users to monitor, track , and ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government